Share Wars
Executive Summary
The news that William Haseltine, PhD, the chairman and CEO of Human Genome Sciences Inc. has sold 15% of his holdings in the company for some $65 million-leaving him $300 million in HGS stock-prompted us to take a look at just how well top-tier biotech CEOs have done. Dr. Haseltine's success describes a new biotech fact: for the most part, top-tier biotech CEOs are worth--at the moment--more than Big Pharma CEOs.